Drugs · acquisition-cost intelligence
XIGDUO XR
dapagliflozin and metformin hydrochloride· ingredient dapagliflozinBiguanides· DAPAGLIFLOZIN 10 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1; DAPAGLIFLOZIN 10 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1; DAPAGLIFLOZIN 5 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1; DAPAGLIFLOZIN 5 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$8.75
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-06-03
Same-ingredient options by acquisition cost
Other dapagliflozin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| dapagliflozin | $0.19473 | −$8.55 |
Medicare Part D coverage · CY2026
On 7 plan formularies · typical tier 4
Prior auth 0% · Step therapy 43% · Quantity limit 100% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.